[go: up one dir, main page]

LUC00159I1 - - Google Patents

Info

Publication number
LUC00159I1
LUC00159I1 LUC00159C LUC00159I1 LU C00159 I1 LUC00159 I1 LU C00159I1 LU C00159 C LUC00159 C LU C00159C LU C00159 I1 LUC00159 I1 LU C00159I1
Authority
LU
Luxembourg
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43735742&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00159(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of LUC00159I1 publication Critical patent/LUC00159I1/fr
Publication of LUC00159I2 publication Critical patent/LUC00159I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503—Five-membered rings
    • C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU00159C 2010-01-14 2020-06-16 LUC00159I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29498010P 2010-01-14 2010-01-14
PCT/US2011/021100 WO2011088188A1 (fr) 2010-01-14 2011-01-13 Utilisation d'un agent de modification d'hormones surrénaliennes

Publications (2)

Publication Number Publication Date
LUC00159I1 true LUC00159I1 (fr) 2020-06-16
LUC00159I2 LUC00159I2 (fr) 2021-07-06

Family

ID=43735742

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00159C LUC00159I2 (fr) 2010-01-14 2020-06-16

Country Status (34)

Country Link
US (2) US8609862B2 (fr)
EP (2) EP2523731B1 (fr)
JP (4) JP5602250B2 (fr)
KR (1) KR101412206B1 (fr)
CN (2) CN105440038A (fr)
AU (1) AU2011205290C1 (fr)
BR (1) BR112012017458B1 (fr)
CA (1) CA2786443C (fr)
CL (1) CL2012001961A1 (fr)
CY (2) CY1121320T1 (fr)
DK (1) DK2523731T3 (fr)
ES (1) ES2707596T3 (fr)
HR (1) HRP20190064T1 (fr)
HU (2) HUE041967T2 (fr)
IL (1) IL220804A0 (fr)
LT (2) LT2523731T (fr)
LU (1) LUC00159I2 (fr)
MA (1) MA33904B1 (fr)
ME (1) ME03371B (fr)
MX (2) MX354022B (fr)
NL (1) NL301043I2 (fr)
NO (1) NO2020012I1 (fr)
NZ (1) NZ601077A (fr)
PH (1) PH12012501422B1 (fr)
PL (1) PL2523731T3 (fr)
PT (1) PT2523731T (fr)
RS (1) RS58234B1 (fr)
RU (1) RU2598708C2 (fr)
SG (1) SG182393A1 (fr)
SI (1) SI2523731T1 (fr)
TN (1) TN2012000352A1 (fr)
TR (1) TR201900515T4 (fr)
WO (1) WO2011088188A1 (fr)
ZA (1) ZA201205058B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20190064T1 (hr) * 2010-01-14 2019-03-08 Novartis Ag Uporaba sredstva za modifikaciju adrenalnog hormona
KR20130135820A (ko) 2010-06-16 2013-12-11 엠베라 뉴로 테라퓨틱스 인코포레이티드 중독，정신 장애 및 신경퇴행성 질환 치료용 조성물 및 방법
TWI518073B (zh) 2011-06-14 2016-01-21 美國禮來大藥廠 醛固酮合成酶抑制劑
WO2013043520A1 (fr) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Composés triazolopyridyle à utiliser en tant qu'inhibiteurs de l'aldostérone synthase
US20140235667A1 (en) 2011-09-22 2014-08-21 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
US9351973B2 (en) 2011-09-22 2016-05-31 Merck Sharp & Dohme Corp. Pyrazolopyridyl compounds as aldosterone synthase inhibitors
PE20142358A1 (es) * 2012-01-17 2015-01-30 Novartis Ag Nuevas formas y sales de un dihidropirrolo[1,2-c]imidazolilo, inhibidor de la aldosterona sintasa o aromatasa
IN2014DN09240A (fr) 2012-04-12 2015-07-10 Novartis Ag
CA2886117C (fr) 2012-10-05 2022-05-31 Merck Sharp & Dohme Corp. Composes d'indoline utilises comme inhibiteurs de l'aldosterone synthase
JP2015093832A (ja) * 2013-11-08 2015-05-18 日本メジフィジックス株式会社 放射性ハロゲン標識化合物又はその塩、これを含む医薬
MX2016017315A (es) * 2014-07-07 2017-04-27 Novartis Ag Formas de dosificacion farmaceutica.
WO2016048984A1 (fr) * 2014-09-25 2016-03-31 Cortendo Ab (Publ) Méthodes et compositions pour le traitement du syndrome de cushing basées sur le 2s,4r kétoconazole
AU2016210899B2 (en) * 2015-01-29 2019-03-07 Recordati Ag Process for the production of condensed imidazolo Derivatives
US20160287565A1 (en) 2015-04-06 2016-10-06 Millendo Therapeutics, Inc. Combination therapy for treating disorders associated with excess cortisol production
CA2990413A1 (fr) * 2015-06-22 2016-12-29 Embera Neurotherapeutics, Inc. Compositions et procedes pour le traitement de troubles d'utilisation de substances, d'accoutumance, et de troubles psychiatriques
AU2018230521B2 (en) 2017-03-10 2022-02-03 Embera Neurotherapeutics, Inc. Pharmaceutical compositions and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889861A (en) * 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4814333A (en) 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
US5503843A (en) 1994-04-22 1996-04-02 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
US5658881A (en) 1994-10-14 1997-08-19 Twk, Inc. Method for topical inhibition of the metabolic activity of cytochrome P450
DE19814087A1 (de) * 1998-03-30 1999-10-14 Lohmann Therapie Syst Lts Feuchtigkeitsaktivierbares therapeutisches System
US7417038B1 (en) 1998-10-15 2008-08-26 Imperial Innovations Limited Methods of treating cachexia
ES2275853T3 (es) 2001-02-16 2007-06-16 Aventis Pharmaceuticals Inc. Derivados heterociclicos de urea y su uso como ligandos de receptores de dopamina d3.
TWI263640B (en) 2001-12-19 2006-10-11 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
JP5138875B2 (ja) 2005-07-19 2013-02-06 株式会社デンソー センサ装置
GT200600381A (es) * 2005-08-25 2007-03-28 Compuestos organicos
AR056888A1 (es) 2005-12-09 2007-10-31 Speedel Experimenta Ag Derivados de heterociclil imidazol
CA2645678A1 (fr) 2006-03-16 2007-09-20 Yeda Research And Development Co. Ltd. Procede et composition pour la protection du tissu neuronal de degats induits par des niveaux eleves de glutamate
US20100240641A1 (en) * 2006-05-26 2010-09-23 Julien Papillon Aldosterone Synthase and/or 11B-hydroxylase Inhibitors
EP1886695A1 (fr) 2006-06-27 2008-02-13 Speedel Experimenta AG Combinaisons pharmacéutiques avec inhibiteurs de l'aldosterone synthase et antagonistes du recepteur de glucocorticoides où inhibiteurs de la synthese de cortisol où antagonistes du facteur de libération de la corticotropine
AU2007290695A1 (en) * 2006-08-25 2008-03-06 Novartis Ag Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase
EP2121652A1 (fr) * 2006-12-18 2009-11-25 Novartis AG Dérivés de 4-imidazolyle-1,2,3,4-tétrahydroquinoline et leur utilisation comme inhibiteurs de l'aldostérone / 11bêta-hydroxylase
EP2095819A1 (fr) * 2008-02-28 2009-09-02 Maastricht University Dérivés de N-benzyle imidazole et leur utilisation comme inhibiteurs de l'aldosterone synthase
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
HRP20190064T1 (hr) * 2010-01-14 2019-03-08 Novartis Ag Uporaba sredstva za modifikaciju adrenalnog hormona
PE20142358A1 (es) * 2012-01-17 2015-01-30 Novartis Ag Nuevas formas y sales de un dihidropirrolo[1,2-c]imidazolilo, inhibidor de la aldosterona sintasa o aromatasa
IN2014DN09240A (fr) * 2012-04-12 2015-07-10 Novartis Ag

Also Published As

Publication number Publication date
US8609862B2 (en) 2013-12-17
NL301043I2 (nl) 2020-07-06
NO2020012I1 (no) 2020-06-09
AU2011205290C1 (en) 2014-11-06
US20140171392A1 (en) 2014-06-19
TN2012000352A1 (en) 2014-01-30
RS58234B1 (sr) 2019-03-29
US20120295888A1 (en) 2012-11-22
JP6181610B2 (ja) 2017-08-16
CA2786443A1 (fr) 2011-07-21
EP2523731B1 (fr) 2018-10-24
SI2523731T1 (sl) 2019-02-28
HUS2000018I1 (hu) 2020-07-28
CA2786443C (fr) 2018-12-11
EP3527208A1 (fr) 2019-08-21
DK2523731T3 (en) 2019-02-04
JP2018150326A (ja) 2018-09-27
PH12012501422B1 (en) 2018-09-12
LTPA2020512I1 (lt) 2020-07-27
CN105440038A (zh) 2016-03-30
AU2011205290A1 (en) 2012-08-02
NZ601077A (en) 2014-07-25
MA33904B1 (fr) 2013-01-02
CY1121320T1 (el) 2020-05-29
PT2523731T (pt) 2019-01-21
CY2020018I1 (el) 2020-11-25
JP2013517280A (ja) 2013-05-16
JP2017002063A (ja) 2017-01-05
HUS000508I2 (hu) 2021-03-29
CN102711916B (zh) 2015-09-02
CY2020018I2 (el) 2020-11-25
KR101412206B1 (ko) 2014-06-25
IL220804A0 (en) 2012-08-30
JP2015013859A (ja) 2015-01-22
ME03371B (fr) 2020-01-20
LT2523731T (lt) 2019-02-11
JP5602250B2 (ja) 2014-10-08
BR112012017458A2 (pt) 2017-12-19
MX2012008212A (es) 2012-08-03
JP6425688B2 (ja) 2018-11-21
ES2707596T3 (es) 2019-04-04
CL2012001961A1 (es) 2013-03-22
CN102711916A (zh) 2012-10-03
BR112012017458B1 (pt) 2020-10-20
NL301043I1 (nl) 2020-06-17
TR201900515T4 (tr) 2019-02-21
RU2012134510A (ru) 2014-02-20
MX354022B (es) 2018-02-08
LTC2523731I2 (lt) 2022-05-10
ZA201205058B (en) 2014-04-30
PL2523731T3 (pl) 2019-04-30
LUC00159I2 (fr) 2021-07-06
HRP20190064T1 (hr) 2019-03-08
PH12012501422A1 (en) 2012-10-22
KR20120116482A (ko) 2012-10-22
HUE041967T2 (hu) 2019-06-28
WO2011088188A1 (fr) 2011-07-21
AU2011205290B2 (en) 2014-06-26
EP2523731A1 (fr) 2012-11-21
US9434754B2 (en) 2016-09-06
SG182393A1 (en) 2012-08-30
RU2598708C2 (ru) 2016-09-27

Similar Documents

Publication Publication Date Title
LUC00159I1 (fr)
BR112013008959A2 (fr)
BR112012030039A2 (fr)
BR112012019354A2 (fr)
BR112012028408A2 (fr)
BR112012029986A2 (fr)
BR112012027808A2 (fr)
BR112012024897A2 (fr)
BR112012026492A2 (fr)
BR112012031500A2 (fr)
BR112012025307A2 (fr)
BR112012017960A2 (fr)
BR112012002126A2 (fr)
BR112012026946A2 (fr)
BR112012025482A2 (fr)
BR112013006400A2 (fr)
BR112012023249A2 (fr)
BR112012028186A2 (fr)
BR112012025577A2 (fr)
BR112012016456A2 (fr)
BR112012018256A2 (fr)
BR112012027015A2 (fr)
BR112012025308A2 (fr)
BR112013010949A2 (fr)
BR112012027945A2 (fr)